Daiwa Securities Group Inc. - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 152 filers reported holding REATA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 3.61 and the average weighting 0.2%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$13
+18.2%
1260.0%0.00%
Q1 2023$11
+175.0%
126
+16.7%
0.00%
Q4 2022$4
-99.9%
1080.0%0.00%
Q3 2022$3,0000.0%1080.0%0.00%
Q2 2022$3,000
-25.0%
1080.0%0.00%
Q1 2022$4,000
+33.3%
1080.0%0.00%
Q4 2021$3,000
-72.7%
1080.0%0.00%
Q3 2021$11,000
+22.2%
108
+74.2%
0.00%
Q2 2021$9,000
+50.0%
620.0%0.00%
Q1 2021$6,000
-14.3%
62
+14.8%
0.00%
Q4 2020$7,000
-56.2%
54
-66.2%
0.00%
Q3 2020$16,000
-27.3%
160
+4.6%
0.00%
Q2 2020$22,0000.0%1530.0%0.00%
Q1 2020$22,000
-29.0%
1530.0%0.00%
Q4 2019$31,000
+158.3%
1530.0%0.00%
Q3 2019$12,000
-14.3%
1530.0%0.00%
Q2 2019$14,000
+7.7%
1530.0%0.00%
Q1 2019$13,000
+116.7%
153
+39.1%
0.00%
Q4 2018$6,000
-33.3%
1100.0%0.00%
Q3 2018$9,000
+125.0%
1100.0%0.00%
Q2 2018$4,000
+100.0%
1100.0%0.00%
Q1 2018$2,000
-99.8%
110
-99.7%
0.00%
-100.0%
Q1 2017$829,00036,6110.01%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q1 2022
NameSharesValueWeighting ↓
CPMG Inc 2,896,901$291,457,00032.14%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 46,646$4,693,0005.31%
Ikarian Capital, LLC 471,400$47,423,0003.34%
Duquesne Family Office 695,033$69,927,0002.27%
Camber Capital Management LP 685,000$68,918,0002.12%
LBJ Family Wealth Advisors, Ltd. 30,359$3,054,0001.82%
MADDEN SECURITIES Corp 33,127$3,333,0001.80%
Biondo Investment Advisors, LLC 104,120$10,475,0001.80%
Tolleson Wealth Management, Inc. 60,750$6,112,0001.73%
Keel Point, LLC 97,074$9,767,0001.26%
View complete list of REATA PHARMACEUTICALS INC shareholders